SHC012
MISSION® pLKO.1-puro-CMV-TagRFP™ Positive Control Plasmid DNA
Contains a gene encoding TagRFP
Synonym(s):
MISSION® Control Vectors
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Concentration:
500 ng/μL in TE buffer; DNA (10μg of plasmid DNA)
Quality Level
product line
MISSION®
concentration
500 ng/μL in TE buffer; DNA (10μg of plasmid DNA)
shipped in
dry ice
storage temp.
−20°C
General description
Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, we recommend producing self-inactivating replication incompetent viral particles in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. The CMV-TagRFP Control Vector is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.
Application
To see more application data, protocols, vector maps visit sigma.com/shrna.
The MISSION TagRFP Control Vector is an 8594 base pair lentivirus plasmid vector that contains a gene encoding TagRFP, under the control of the CMV promoter. The CMV-TagRFP Control Vector is useful as a positive control in experiments using the MISSION shRNA library clones.
The MISSION TagRFP Control Vector is an 8594 base pair lentivirus plasmid vector that contains a gene encoding TagRFP, under the control of the CMV promoter. The CMV-TagRFP Control Vector is useful as a positive control in experiments using the MISSION shRNA library clones.
Legal Information
Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense.
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
TagRFP is a trademark of Evrogen Co.
Storage Class
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Instructions
Chi Huu Nguyen et al.
Scientific reports, 9(1), 9139-9139 (2019-06-27)
Acute myeloid leukemia (AML) is a heterogeneous disease with respect to its genetic and molecular basis and to patients´ outcome. Clinical, cytogenetic, and mutational data are used to classify patients into risk groups with different survival, however, within-group heterogeneity is